Search research articles
Contact Us
Filters
Showing results (1-10 of 123) with videos related to
Page
of 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 11, 2017
Diarrhoea during checkpoint blockade, not always colitis
Josephine J Koldenhof, Karijn P M Suijkerbuijk
Nature Reviews. Rheumatology
|
June 9, 2021
TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out
Karijn P M Suijkerbuijk, Rik J Verheijden
JAMA Oncology
|
June 20, 2020
Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors
Karijn P M Suijkerbuijk, Ellen Kapiteijn, Rik J Verheijden
JAMA Oncology
|
March 9, 2023
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events-Reply
Olivier J van Not, Rik J Verheijden, Karijn P M Suijkerbuijk
Frontiers in Oncology
|
March 1, 2021
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review
Josefien W Hommes, Rik J Verheijden, Karijn P M Suijkerbuijk, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology
|
June 12, 2008
Molecular analysis of nipple fluid for breast cancer screening
Karijn P M Suijkerbuijk, Elsken van der Wall, Marc Vooijs, et al.
Annals of Internal Medicine
|
September 20, 2021
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease
Monique K van der Kooij, Karijn P M Suijkerbuijk, Olaf M Dekkers, et al.
International Journal of Surgery Case Reports
|
March 17, 2022
Diagnostic pitfalls after COVID-19 vaccination in melanoma and breast cancer patients: A case series
Ellen de Bock, Kari Trumpi, Karijn P M Suijkerbuijk, et al.
Analytical Cellular Pathology (Amsterdam)
|
October 28, 2010
Comparison of different promoter methylation assays in breast cancer
Karijn P M Suijkerbuijk, Xiaojuan Pan, Elsken van der Wall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 20, 2022
Metachronous malignancies after response to checkpoint inhibition
Mirjam A de Visser, Francois B Verschaeve, Lot A Devriese, et al.
Page
of 13
Search research articles
Search
Showing results (1-10 of 123) with videos related to
Sort By:
Page
of 13
European Journal of Cancer (Oxford, England : 1990)
|
October 11, 2017
Diarrhoea during checkpoint blockade, not always colitis
Josephine J Koldenhof, Karijn P M Suijkerbuijk
Nature Reviews. Rheumatology
|
June 9, 2021
TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out
Karijn P M Suijkerbuijk, Rik J Verheijden
JAMA Oncology
|
June 20, 2020
Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors
Karijn P M Suijkerbuijk, Ellen Kapiteijn, Rik J Verheijden
JAMA Oncology
|
March 9, 2023
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events-Reply
Olivier J van Not, Rik J Verheijden, Karijn P M Suijkerbuijk
Frontiers in Oncology
|
March 1, 2021
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review
Josefien W Hommes, Rik J Verheijden, Karijn P M Suijkerbuijk, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology
|
June 12, 2008
Molecular analysis of nipple fluid for breast cancer screening
Karijn P M Suijkerbuijk, Elsken van der Wall, Marc Vooijs, et al.
Annals of Internal Medicine
|
September 20, 2021
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease
Monique K van der Kooij, Karijn P M Suijkerbuijk, Olaf M Dekkers, et al.
International Journal of Surgery Case Reports
|
March 17, 2022
Diagnostic pitfalls after COVID-19 vaccination in melanoma and breast cancer patients: A case series
Ellen de Bock, Kari Trumpi, Karijn P M Suijkerbuijk, et al.
Analytical Cellular Pathology (Amsterdam)
|
October 28, 2010
Comparison of different promoter methylation assays in breast cancer
Karijn P M Suijkerbuijk, Xiaojuan Pan, Elsken van der Wall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 20, 2022
Metachronous malignancies after response to checkpoint inhibition
Mirjam A de Visser, Francois B Verschaeve, Lot A Devriese, et al.
Page
of 13